Company: OTSA
Filing Date: 2025-07-16
Form Type: F-1/A
Source: 0001213900-25-064434
Chunk: 163

Company: OTSAW Ltd
Filing Date: 2025-07-16
Form: F-1/A
Chunk 163
---
. The purpose of the one -yeartrial was to penetrate the last -miledelivery and logistics market of Singapore with our AMR solution, Camello. On May21, 2020, we entered into a research collaboration agreement (“RCA”) with the Singapore Institute of Manufacturing Technology (“SIMTech”), a national research institution under the Singapore Agency for Science, Technology and Research (“A*STAR”). This partnership focuses on designing and developing O -RX, an advanced robotic solution for disinfection and sanitization, that we believe addresses critical hygiene and safety needs, and was especially practical during the pandemic. Under the RCA, SIMTech was responsible for designing the UV -CLED technology, including the layout of the UV -CLED lights for disinfection and the associated heat management system, while we were responsible for the robot and software system design, production, and commercialization of the technology. The project ran for a period of 16 weeks. The RCA provides that any resulting solution is to be jointly patented, with intellectual property ownership shared equally between the parties. Pursuant to the RCA, patent applications were filed in Singapore and the United States relating to the UV -CLED technology, which powers our UV -Cdisinfection products such as O -RXand TreX. The O -RXproduct line has since been discontinued, and only a total of 3 TreX products has been sold as of the date of this prospectus. The costs associated with the filing of the patents were shared equally by the parties. We also agreed to pay SIMTech a royalty fee in connection with the use of the technology. To date, the aggregate amount of project -relatedpayments made by us under the RCA is approximately US$32,700 (S$43,157), and the agreed royalty fee paid or payable is approximately US$33,800 (S$44,593). We continue to grow through allying with channel partners and strategic investors globally, enabling us to be more agile in achieving our goals in the shortest time by leveraging on our technological strength and our partners’ connections and relationship. We plan to pursue strategic co -developmentopportunities and arrangements that further enhance our product pipeline to create effective synergies to supplement our AMRs and robotics ecosystem. Our collaborations with industry players provide valuable knowledge that we believe will enhance our early mover advantage. Growth Strategies Developing Our Core Software Technologies and Commercialize Our Up-and -Coming ANS Version 3, the Odyssey, to the Entire AMR and Robotics Industry We will continue to make significant investments in